Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 64Breast Neoplasms 20Kidney Neoplasms 19Gastrointestinal Stromal Tumors 16Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Colorectal Neoplasms 6Neuroendocrine Tumors 5Carcinoma, Hepatocellular 5Carcinoma 5Thyroid Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Kidney Diseases 3Glioblastoma 3Esophageal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Astrocytoma 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3

Interventions

pralsetinib 2pembrolizumab 2Brentuximab Vedotin 2Bevacizumab 2ribociclib 1fosaprepitant 1Sunitinib 1Sirolimus 1Radiotherapy, Image-Guided 1Plicamycin 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Genistein 1Gemcitabine 1Erlotinib Hydrochloride 1Dexamethasone 1Cisplatin 1Carboplatin 1Aprepitant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Germ Cell and Embryonal × Sunitinib × Clear all
NCT00912912 2016-04-15

Sunitinib Malate in Refractory Germ Cell Tumors

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 6 charts

Urogenital Diseases, Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡